A Novel Method for Monitoring Anticoagulation with Warfarin

A modified test based on reductions in factor II and factor X was associated with a 56% reduction in total thromboembolic events.

Variability in the prothrombin time/international normalized ratio (PT/INR) presents challenges for physicians and frustrations for patients anticoagulated with warfarin. Fluctuations in the PT/INR may result from reductions in factor VII, but the antithrombotic effect of warfarin is likely caused by reductions in factors II and X. Fluctuating PT/INR values can lead to changes in safety and efficacy of treatment as well as additional lab testing.

Investigators created a modified test, the Fiix-PT, that is influenced by reductions in factor II and factor X, but not factor VII. The test has been used in Iceland since 2016. To evaluate its effect in clinical practice, the investigators studied a dynamic cohort of 2667 patients on maintenance wa…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

A Novel Method for Monitoring Anticoagulation with Warfarin

Topics

Reviewing Author